Placeholder Banner

Biotech Companies Express Concern With Proposed Changes to the Medicaid Drug Rebate Program (MDRP)

April 11, 2024

We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry and create extensive barriers to patient access to existing innovative therapies and to developing new cures for Medicaid enrollees.1 As a result, it will deny some of the nation's most vulnerable patients access to the state-of-the-art medical care they deserve, both now and in the future.

Download Full Comments Below
Biotech Companies Express Concern With Proposed changes to the Medicaid Drug Rebate Program
Discover More
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO comments on a proposed rule to restrict planting of GE organisms on national wildlife refuge lands. 
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.